scholarly journals Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer

2012 ◽  
Vol 21 (21) ◽  
pp. 4669-4679 ◽  
Author(s):  
T. Hansmann ◽  
G. Pliushch ◽  
M. Leubner ◽  
P. Kroll ◽  
D. Endt ◽  
...  
2017 ◽  
Vol 167 (3) ◽  
pp. 803-814 ◽  
Author(s):  
Rafael Canfield Brianese ◽  
Kivvi Duarte de Mello Nakamura ◽  
Fernanda Gabriella dos Santos Ramos Almeida ◽  
Rodrigo Fernandes Ramalho ◽  
Bruna Durães de Figueiredo Barros ◽  
...  

2015 ◽  
Vol 61 (5) ◽  
pp. 474-483 ◽  
Author(s):  
Giselly Encinas ◽  
Simone Maistro ◽  
Fátima Solange Pasini ◽  
Maria Lucia Hirata Katayama ◽  
Maria Mitzi Brentani ◽  
...  

Summary Objective: our aim was to evaluate whether somatic mutations in five genes were associated with an early age at presentation of breast cancer (BC) or serous ovarian cancer (SOC). Methods: COSMIC database was searched for the five most frequent somatic mutations in BC and SOC. A systematic review of PubMed was performed. Young age for BC and SOC patients was set at ≤35 and ≤40 years, respectively. Age groups were also classified in <30years and every 10 years thereafter. Results: twenty six (1,980 patients, 111 younger) and 16 studies (598, 41 younger), were analyzed for BC and SOC, respectively. In BC, PIK3CA wild type tumor was associated with early onset, not confirmed in binary regression with estrogen receptor (ER) status. In HER2-negative tumors, there was increased frequency of PIK3CA somatic mutation in older age groups; in ER-positive tumors, there was a trend towards an increased frequency of PIK3CA somatic mutation in older age groups. TP53 somatic mutation was described in 20% of tumors from both younger and older patients; PTEN, CDH1 and GATA3 somatic mutation was investigated only in 16 patients and PTEN mutation was detected in one of them. In SOC, TP53 somatic mutation was rather common, detected in more than 50% of tumors, however, more frequently in older patients. Conclusion: frequency of somatic mutations in specific genes was not associated with early-onset breast cancer. Although very common in patients with serous ovarian cancer diagnosed at all ages, TP53 mutation was more frequently detected in older women.


2022 ◽  
Author(s):  
Lili Chen ◽  
Meng Huang ◽  
Minyan Chen ◽  
Yuxiang Lin ◽  
Jing Li ◽  
...  

Abstract Background: Except for BRCA1/2, there is no data on the relationship between genetic counseling for the range of mutations and early-onset breast cancer populations. We looked for a link between inherited genes and the molecular subtype of early-onset breast cancer.Methods: We genotyped 1214 individuals with early-onset sporadic breast cancer (age≤40 years) who were BRCA1/2-negative in 3 genes: TP53, PALB2, and RECQL. We focus on the immunohistochemistry characteristics that are unique to each patient. Results: The mutation rates of TP53, PALB2, and RECQL in 1214 BRCA-negative young individuals were 4/1214(0.33%), 8/1214(0.66%), 2/1214(0.16%), respectively. The fact that the TP53 mutation rate was 3.49% among estrogen receptor-and/or progesterone receptor-positive, human epidermal growth factor receptor 2 (HER-2) amplification patients under the age of 35 (P<0.001) was particularly noteworthy. Conclusion: According to the findings, TP53 genetic testing should focus on women under 35 with HR-positive and HER2-positve IDC patients.


2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Nana Weber-Lassalle ◽  
Julika Borde ◽  
Konstantin Weber-Lassalle ◽  
Judit Horváth ◽  
Dieter Niederacher ◽  
...  

2015 ◽  
Vol 63 (4-5) ◽  
pp. 185-189 ◽  
Author(s):  
N. Hadiji-Abbes ◽  
F. Trifa ◽  
M. Choura ◽  
A. Khabir ◽  
T. Sellami-Boudawara ◽  
...  

2019 ◽  
Author(s):  
N Weber-Lassalle ◽  
J Borde ◽  
K Weber-Lassalle ◽  
J Horváth ◽  
D Niederacher ◽  
...  

2018 ◽  
Vol 20 (1) ◽  
Author(s):  
Nana Weber-Lassalle ◽  
Jan Hauke ◽  
Juliane Ramser ◽  
Lisa Richters ◽  
Eva Groß ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document